

Printed as of 5/9/2025

Disclosures

Personal Commercial (27)						
Company Name	Relationship Category	Compensation Level	Topic Area(s)			
Self						
CVR Consulting	Consultant Fees/Honoraria	Consultant Fees/Honoraria Significant (>= \$5,000)				
Sommetrics	Consultant Fees/Honoraria	None (\$0)	Other			
Spouse/Domestic Partner/Immediate Household Member						
Acceleron	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Acceleron	Consultant Fees/Honoraria	onsultant Fees/Honoraria Modest (< \$5,000)				
Aerovate	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Altavant	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Altavant	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Express Scripts	Consultant Fees/Honoraria	Modest (< \$5,000)	Other			
Ferrer	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Gossamer	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Gossamer	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Impact PH	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Johnson & Johnson	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Johnson & Johnson	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Liquidia	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Medtronic	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Merck	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Phase Bio	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Phase Bio	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Simply Speaking	Speaker's Bureau	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Trio Analytics	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
United Therapeutics	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Vaderis	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
Vaderis	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			
V-wave	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic			

Company Name	Relationship Category	Compensation Level	Topic Area(s)
WebMD, LLD	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (12)

Non-Commercial Enity Name	Relationship Category Compensation Level		Topic Area(s)	
Self				
American College of Cardiology	Other - AHA/ACC JCCPG	None (\$0)	General Cardiology	
American Heart Association	Other - Member, Journal Equity, Diversity, and Inclusion Editorial Board	Significant (>= \$5,000)	General Cardiology	
American Heart Association	Other - SFRN HF Oversight & Action Committee; AHA/ACC JCCPG	None (\$0)	General Cardiology Heart Failure and Cardiomyopathies	
American Heart Association - Circulation Journals	Other - Editorial Board, Circulation: Cardiovascular Imaging	Significant (>= \$5,000)	General Cardiology Noninvasive Imaging	
Foundation for the National Institutes of Health	Other - Scientific Working Group	None (\$0)	Heart Failure and Cardiomyopathies	
National Institutes of Health	Research/Research Grants ‡ Chronic Non-communicable CVDs and Comorbidities in Peru	Significant (>= \$5,000)	General Cardiology Prevention Other	
National Institutes of Health	Research/Research Grants	Significant (>= \$5,000)	General Cardiology Prevention Other	
Spouse/Domestic Partner/Immediate Household Member				
Cure HHT	Other - Senior Clinical Advisor	Significant (>= \$5,000)	Other	
National Institutes of Health	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic	
Pulmonary Hypertension Association	Other - CME Material Review	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic	
University of Kentucky DSMB providing oversight for Vanderbilt University study	Data Safety Monitoring Board	None (\$0)	Pulmonary Hypertension and Venous Thromboembolic	
University of Toronto	Data Safety Monitoring Board	None (\$0)	Pulmonary Hypertension and Venous Thromboembolic	

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation	
Spouse	Spouse/Domestic Partner/Immediate Household Member				
2022	Patent infringement	Plaintiff † Johnson & Johnson	Patent infringement in Canada for drug used to treat pulmonary hypertension	Significant (>= \$5,000)	

† Commercial Funding Source | *‡* Trial Name

Agreement

Certified Education Attestation | Signed on 8/18/2020 URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/18/2020 URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/18/2020 URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 12/14/2022

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.